Ekspresja CD74 na limfocytach krwi obowodowej, węzlów chlonnych, naciekających guz u pacjentów chorych na NDRP

Abstract

Author(s): Mariusz Stram, Jacek Tabarkiewicz, Paweł Rybojad, Mariusz Kędra, Marek Sawicki, Jacek Roliński

Introduction: MIF (macrophage migration inhibitory factor) is the cytokine overexpressed in lung cancer and interaction between MIF and it’s receptor could be associated with angiogenic activity. The MIF receptor (CD74) was recently discovered and found to be the invariant chain of the HLA class II molecule. Moreover, it has recently been shown to have a role as an accessory-signaling molecule and has been implicated in malignant B-cell proliferation, survival and as target for immunotherapy.

The aim of the study: The aim of our study was to determine expression of CD74 in B-cell isolated from tissues of patients with non-small cell lung cancer (NSCLC).

Material and methods: Mononuclear leukocytes were isolated from peripheral blood (PB), lymph nodes (LN) and cancer tissue (CT). Additionally results from PB were compared to results from blood of healthy donors (HD).

Results: We found that CD19+/CD74+ lymphocytes are accumulated in the tissues directly involved in cancer process: LN and CT, when compared to PB. We also found that percentage of CD19+/CD74+ cells was significantly higher in PB of NSCLC patients than in HD.

Conclusions: Our results stay in accordance with reports describing involve of CD74 in cancerogenesis and could suggest that infiltration with CD74+ B cells could be phenomenon included in cancer “immunoescape”. Our results stay in accordance with publications describing negative role of B lymphocytes in anti-cancer immune response.

Share this article